Log in

CVE:ACSTAcasti Pharma Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
C$0.64
MA: C$0.92
C$1.20
52-Week Range N/A
Volume82,309 shs
Average Volume192,563 shs
Market CapitalizationC$88.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-6864555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueC$0.14 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$88.79 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acasti Pharma (CVE:ACST) Frequently Asked Questions

Has Acasti Pharma been receiving favorable news coverage?

Media headlines about ACST stock have trended somewhat positive on Thursday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acasti Pharma earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Acasti Pharma
.

Who are some of Acasti Pharma's key competitors?

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Amarin (AMRN), SCYNEXIS (SCYX), Square (SQ), Aurora Cannabis (ACB), ADMA Biologics (ADMA), Blackline (BL), Chewy (CHWY), Crowdstrike (CRWD), Editas Medicine (EDIT) and General Electric (GE).

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:
  • Ms. Janelle D' Alvise, Pres, CEO & Director
  • Dr. Pierre Lemieux, Co-Founder and Chief Operating & Scientific Officer
  • Mr. Jean-François Boily, VP of Fin.
  • Mr. Brian James Groch, Chief Commercial Officer (Age 52)

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of C$0.00.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.